Oseltamivir Accord (Oseltamivir)

Oseltamivir Accord is an antiviral medication that targets influenza viruses.

• Influenza A infection: Reduces severity and duration of symptoms in patients with confirmed flu.
• Influenza B infection: Helps shorten illness course and alleviates fever and aches.
• Post‑exposure prophylaxis: Prevents onset of flu in individuals who have been exposed to the virus.

• Oseltamivir is a neuraminidase inhibitor that binds to the active site of the viral neuraminidase enzyme, blocking its ability to cleave sialic acid residues. This inhibition prevents the release of newly formed viral particles from infected cells, limiting viral spread within the respiratory tract and reducing the overall viral load.

Oseltamivir Accord may cause a range of adverse reactions, most of which are mild and self‑limiting.

Common Side Effects

• Nausea: Mild to moderate stomach upset.
• Vomiting: Occasional episodes, especially when treatment is started.
• Headache: Transient headache reported by some patients.
• Diarrhea: Loose stools that resolve without intervention.
• Abdominal pain: Discomfort in the stomach area.

Serious or Rare Side Effects

• Allergic reaction: Rash, itching, swelling, or difficulty breathing.
• Neuropsychiatric events: Unusual behavior, delirium, or hallucinations, primarily reported in pediatric cases.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Hepatic dysfunction: Elevated liver enzymes indicating liver stress.
• Anaphylaxis: Rapid onset of life‑threatening allergic response.

When prescribing Oseltamivir Accord, clinicians should consider several safety aspects.

• Renal impairment: Adjust dose in patients with reduced kidney function.
• Pregnancy: Use only if clearly needed; weigh potential benefits against risks.
• Breastfeeding: Monitor infant for possible adverse effects if mother is treated.
• Age considerations: Safety data are limited for children under one year of age.
• Concomitant medications: Review for potential drug‑drug interactions.
• Store at below 25°C: Keep in the original packaging, protect from moisture and direct sunlight.

Oseltamivir may interact with other medicines; awareness of interaction severity helps guide monitoring.

Major Interactions (Avoid)

• Probenecid: Increases oseltamivir plasma levels, raising toxicity risk.

Moderate Interactions (Monitor Closely)

• Antiviral combination therapy: May alter effectiveness of each agent.
• Live attenuated influenza vaccine (LAIV): Potential reduction of vaccine efficacy.
• Warfarin: May require INR monitoring due to possible effect on coagulation.
• Corticosteroids: May increase risk of neuro‑psychiatric side effects.
• Antacids containing aluminum or magnesium: May affect drug absorption.